MindMed to Participate at May Investor Conferences

Published

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

  • 2024 RBCCM Global Healthcare Conference
  • HCW's 2nd Annual BioConnect Investor Conference
    • Format: 1x1 investor meetings only
    • Date: May 20, 2024
    • Location: New York, NY

An audio webcast and replay of the fireside chat at the 2024 RBCCM Global Healthcare Conference will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

For Media: media@mindmed.co For Investors: ir@mindmed.co

Source: MindMed

In This Story

MNMD